* Advanced Magnetics Inc., of Cambridge, Mass., terminated amarketing agreement with Sterling Winthrop Inc., of New York, forFeridex, a magnetic resonance imaging contrast agent for detectingliver cancer. The agreement was discontinued after Sterling sold itsethical pharmaceutical business.* Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., has raised$3.6 million in the private placement of convertible preferred stock.u ProCyte Corp., of Kirkland, Wash., reported that Phase I/II trialsof Iamin-IB for inflammatory bowel disease showed 60 percent ofthe 16 patients experienced symptomatic improvement in theirconditions and 80 percent experienced reduction in inflammation.The company said evidence showed the treatment also was safe.

(c) 1997 American Health Consultants. All rights reserved.